Cite
Sprooten J, Vankerckhoven A, Vanmeerbeek I, et al. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. J Immunother Cancer. 2021;9(11)doi: 10.1136/jitc-2021-003609.
Sprooten, J., Vankerckhoven, A., Vanmeerbeek, I., Borras, D. M., Berckmans, Y., Wouters, R., Laureano, R. S., Baert, T., Boon, L., Landolfo, C., Testa, A. C., Fischerova, D., Van Holsbeke, C., Bourne, T., Chiappa, V., Froyman, W., Schols, D., Agostinis, P., Timmerman, D., Tejpar, S., Vergote, I., Coosemans, A., & Garg, A. D. (2021). Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. Journal for immunotherapy of cancer, 9(11), . https://doi.org/10.1136/jitc-2021-003609
Sprooten, Jenny, et al. "Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer." Journal for immunotherapy of cancer vol. 9,11 (2021). doi: https://doi.org/10.1136/jitc-2021-003609
Sprooten J, Vankerckhoven A, Vanmeerbeek I, Borras DM, Berckmans Y, Wouters R, Laureano RS, Baert T, Boon L, Landolfo C, Testa AC, Fischerova D, Van Holsbeke C, Bourne T, Chiappa V, Froyman W, Schols D, Agostinis P, Timmerman D, Tejpar S, Vergote I, Coosemans A, Garg AD. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003609. PMID: 34795003; PMCID: PMC8603275.
Copy
Download .nbib